Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 403 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adverse Symptoms Clear all
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

Lifeflight: Fentanyl Versus Morphine

NCT00580489
View directory record Official record
Conditions
Pain Relief, Adverse Events
Interventions
either fentanyl or morphine
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
management of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
105
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jul 22, 2026, 4:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sorrel 25R Injector - Sorrel Clinical Study Protocol

NCT05221333
View directory record Official record
Conditions
Injection Site, Injection Site Reaction, Injection Site Irritation
Interventions
Sorrel Wearable Injector
Device
Lead sponsor
Eitan Medical
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

NCT00255879
View directory record Official record
Conditions
Dyskinesia, Drug-Induced
Interventions
Quetiapine, Risperidone, Olanzapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Phase 2 Interventional

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

NCT05730283
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
ORC-13661, Placebo
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated No phase listed Observational Results available

Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease

NCT01320072
View directory record Official record
Conditions
Asthma, Aspirin-induced
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

NCT00419445
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
GTS21/Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Smell Changes & Efficacy of Nasal Theophylline

NCT03990766
View directory record Official record
Conditions
Olfactory Disorder, Anosmia, Viral Infection, Theophylline Causing Adverse Effects in Therapeutic Use, Smell Disorder
Interventions
Theophylline, Saline Nasal
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 4:57 AM EDT
Suspended Early Phase 1 Interventional

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

NCT05756660
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
Sodium Thiosulfate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 39 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated Phase 2Phase 3 Interventional

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT05116813
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Augusta, Georgia • Kansas City, Kansas • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Vestibular Implantation in Older Adults

NCT05676944
View directory record Official record
Conditions
Other Disorders of Vestibular Function, Bilateral, Bilateral Vestibular Deficiency (BVD), Gentamicin Ototoxicity, Labyrinth Diseases, Vestibular Diseases, Sensation Disorders, Bilateral Vestibular Hypofunction, Bilateral Vestibulopathy, Presbyvestibulopathy, Aminoglycoside Ototoxicity
Interventions
Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Achieving Chronic Care equiTy by leVeraging the Telehealth Ecosystem

NCT06598436
View directory record Official record
Conditions
Diabetes
Interventions
Digital Health Coaching (Patient-Level Intervention), Practice Facilitation (Clinic-Level Intervention)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

NCT05838638
View directory record Official record
Conditions
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions
eSSET-CINV
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00093353
View directory record Official record
Conditions
Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
Interventions
cefixime, irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Not yet recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 4:57 AM EDT
Withdrawn Phase 2 Interventional

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

NCT00003407
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Chicago, Illinois • Kankakee, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

The Platinum Study Comparison Group

NCT02890030
View directory record Official record
Conditions
Testicular Neoplasms
Interventions
Questionnaire
Behavioral
Lead sponsor
Lawrence Einhorn
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00061776
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Jul 22, 2026, 4:57 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 22, 2026, 4:57 AM EDT
Completed No phase listed Observational

Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders

NCT04060121
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Constipation
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Life Experiences in Adolescents and the Development of Skills

NCT04719897
View directory record Official record
Conditions
Depression in Adolescence, Adverse Childhood Experiences
Interventions
FIRST: Repairing Thoughts
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 15 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 22, 2026, 4:57 AM EDT
Completed Not applicable Interventional Results available

The Gore SCAFFOLD Clinical Study

NCT01901874
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Artery Stenosis
Interventions
Carotid Artery Stenting
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Honolulu, Hawaii • Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Jul 22, 2026, 4:57 AM EDT